



BlackRock Asset Allocation Alpha Fund update

11 JUNE 2013

Transition to a replacement fund

As you may be aware, BlackRock Investment Management (Australia) has now terminated the BlackRock Asset Allocation Alpha Fund (the 'BlackRock Fund'). This is the underlying fund in which the BlackRock Asset Allocation Alpha Fund invests.

Following an extensive review to identify a suitable replacement for the underlying BlackRock Fund, we are pleased to announce that we will be transitioning the underlying assets to the GMO Systematic Global Macro Fund during June 2013. Effective 1 July 2013, the name of the BlackRock Asset Allocation Alpha Fund available through ANZ Super Advantage will change to the OnePath Alternatives Growth Fund.

The new underlying fund, the GMO Systematic Global Macro Fund, is highly rated by external research houses and has an impressive track record of strong investment performance. It has a similar investment strategy and asset class exposure to the previous BlackRock Fund.

Why is the BlackRock Fund being replaced?

On 25 February 2013, BlackRock Investment Management (Australia) Limited announced that the BlackRock Fund would be terminating.

At that time, we advised our intention to undertake the process of identifying a suitable replacement fund for investors' assets in the BlackRock Asset Allocation Alpha Fund, which was wholly invested in the underlying BlackRock Fund. [Click here](#) for more detail on the termination.

We have now received the proceeds from the termination of the underlying BlackRock Fund. These proceeds are being held in cash pending transition to the replacement fund. BlackRock investment management fees have been waived since 25 February 2013.

When will the transition take place?

The transition of underlying assets will take place during June 2013.

What will the transition mean for existing ANZ Super Advantage investors?

- The underlying investments will automatically be transitioned to the GMO Systematic Global Macro Fund during June 2013.
- Investors will continue to hold the same asset class exposure following the transition.
- Investors will see no change in the number of units they hold, nor will they see a transaction appear in their account. The unit prices of the impacted funds will continue post transition, i.e. unit prices are not restarted or reset.
- Investors will see the name of the BlackRock Asset Allocation Alpha Fund change to OnePath Alternatives Growth Fund in correspondence from OnePath and in online reporting and transacting from 1 July 2013.
- There will be no tax implications as a result of the transition.
- There will be no transaction costs in relation to the transition as the GMO Systematic Global Macro Fund does not apply a buy/sell spread.



- There will be no change to ongoing fees after the transition.
- The BlackRock Asset Allocation Alpha Fund remains open to all transactions throughout the transition period.
- Until the transition date, the underlying assets will continue to be held in cash. From the transition date, assets will be held in the GMO Systematic Global Macro Fund.

Any questions?

If you have any questions or require further information, please:

- speak with your financial adviser
- call Customer Services on 13 38 63, weekdays between 8.30am and 6.30pm (AEST)
- email customer@onepath.com.au

Which products are affected by this change?

- ANZ Super Advantage

Which product disclosure documents are impacted?

- ANZ Super Advantage Investment Choice Guide

Any questions?

If you have any questions or require further information, please:

- speak with your financial adviser
- call Customer Services on 13 38 63, weekdays between 8.30am and 6.30pm (AEST)
- email customer@onepath.com.au

Additional information on the OnePath Alternatives Growth Fund

Investment objective

The OnePath Alternatives Growth Fund aims to produce a portfolio that seeks to outperform the UBS Australian Bank Bill Index.

Description

The OnePath Alternatives Growth Fund is suitable for investors seeking high total return over a medium to long term period and who are prepared to accept higher variability of returns.

Investment strategy

The OnePath Alternatives Growth Fund plans to pursue its investment objective by investing in a range of equity, bond, commodity and currency markets using exchange traded futures and forward foreign exchange contracts as well as making other investments.

From mid June, the OnePath Alternatives Growth Fund will invest in the GMO Systematic Global Macro Fund.

The Trust seeks to take advantage of GMO Australia's proprietary investment models for global tactical asset allocation and equity, bond, currency and commodity market selection. GMO Australia's models for this active quantitative process are based on the following strategies:

- Value-Based Strategies: Value factors compare the price of an asset class or market to an economic fundamental value. Generally, value-based strategies use yield and mean reversion factors.
- Sentiment-Based Strategies: Generally, sentiment-based strategies assess factors such as risk aversion, analyst behaviour and momentum.

Asset allocation

Asset class	Benchmark (%)	Range (%) *
Cash	100	-155-+155
Fixed interest	0	-155-+155
Equities	0	-80-+80
Commodities	0	-55-+55

Underlying Fund: GMO Systematic Global Macro Trust

* The ranges reflect the overall net exposure that the fund may have to each asset class. The fund may have positive or negative (long/short) net exposure to each asset class. The fund will generally be managed within these ranges although the fund may be outside of these ranges for short periods of time.

Note: the OnePath Alternatives Growth Fund name change, from the BlackRock Asset Allocation Alpha Fund, is effective 1 July 2013.

This information is current at March 2013 but may be subject to change. ANZ Super Advantage is issued by OnePath Custodians Pty Limited (ABN 12 008 508 496, RSE L0000673). The information is of a general nature and does not take into account an investor's personal needs, financial circumstances or objectives. Before acquiring, disposing or deciding whether to continue to hold the product, investors should consider the relevant PDS and any product updates which are available at anz.com or by calling Customer Services on 13 38 63.